From september 2023 on, we participate in the rimagepant study (phase 4), investigating this oral cgrp blocker as an acute or preventive treatment for migraine. If you are interested, please don’t hesitate and contact dr. Kelderman (tim.kelderman@gza.be) or our secretary (03 443 3607 or via the contact form on this site).